IP Library Granted Patent US 7,842,502
Granted Patent B2
US 7,842,502 · App. 12/345,369 · Granted Nov 30, 2010

Use of CXCL6 chemokine for inducing precursor cells into chondrocytes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,842,502
App. No.
12/345,369
Granted
Nov 30, 2010
Kind
B2
Abstract

The present invention disclosed the expression of CXCL6 by cells which are able to form stable cartilage. The invention describes the use of these cells and of CXCL6 to promote cartilage (and underlying bone) formation e.g. in the repair of cartilage or osteochondral defects. The invention further describes the use of chemokines in the modulation of progenitor cell differentiation.

Claims (2)

1. An in vitro method of inducing or restoring differentiation of a mesenchymal stem cell population into chondrocytes, said method comprising the step of administering CXCL6 (chemokine with CXC motif, ligand 6) protein in vitro to said mesenchymal stem cell population, thereby inducing or restoring differentiation of the mesenchymal stem cell population into chondrocytes.

2. The method according to claim 1 , wherein said mesenchymal stem cells are obtained from bone marrow, umbilical cord or synovial membrane.

Assignments (2)
SECURITY AGREEMENT Recorded Jan 23, 2014
From: TIGENIX NV
To: KREOS CAPITAL IV (UK) LIMITED
Reel/Frame 032123/0953 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2009
From: LUYTEN, FRANK; DE BARI, COSIMO; DELL'ACCIO, FRANCESCO
To: TIGENIX N.V.
Reel/Frame 022553/0920 →